ESR1 and breast carcinoma: To understand the mechanism of these two combinations with LUT in common, why LUT+I3C exclusively inhibits ER+ breast cancer, but LUT+CUR only synergistically suppresses TNBC, we further confirmed that this combination of LUT and I3C that reduced ERα protein can be abolished by the specific proteasome inhibitor MG132 in MCF7 cells.